| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Malaria poses a major health risk to people who are exposed to infection in malaria-endemic areas. A randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of Malarone (250 mg of atovaquone/100 mg of proguanil hydrochloride per tablet) for the chemoprophylaxis of Plasmodium falciparum malaria in Zambia. Adult volunteers received a three-day treatment course of Malarone to eliminate pre-existing parasitemia and were then immediately randomized to treatment with either one Malarone tablet daily (n = 136), or one placebo tablet daily (n = 138) for at least 10 weeks. Malaria blood smears were prepared on a weekly basis and a failure of chemoprophylaxis was defined as any subject who had a positive blood smear, or who withdrew from the study due to a treatment-related adverse event. The prophylaxis success rates in the Malarone and placebo groups were 98% and 63%, respectively (P < 0.001). The most commonly reported adverse events with at least a possible causal relationship to study medication were headache and abdominal pain, which occurred with a higher incidence in the placebo group. No subjects were withdrawn from the study due to a treatment-related adverse event. Thus, Malarone appears to have an excellent safety and efficacy profile for the chemoprophylaxis of P. falciparum infection.
This article has been cited by other articles:
|
|
 |
|
  H. Nakato, R. Vivancos, and P. R. Hunter A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria J. Antimicrob. Chemother., November 1, 2007; 60(5): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II) Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Schwartz, M. Parise, P. Kozarsky, and M. Cetron Delayed Onset of Malaria -- Implications for Chemoprophylaxis in Travelers N. Engl. J. Med., October 16, 2003; 349(16): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marra, J. R Salzman, and M. H. Ensom Atovaquone-Proguanil for Prophylaxis and Treatment of Malaria Ann. Pharmacother., September 1, 2003; 37(9): 1266 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. BASCO MOLECULAR EPIDEMIOLOGY OF MALARIA IN CAMEROON. XVII. BASELINE MONITORING OF ATOVAQUONE-RESISTANT PLASMODIUM FALCIPARUM BY IN VITRO DRUG ASSAYS AND CYTOCHROME B GENE SEQUENCE ANALYSIS Am J Trop Med Hyg, August 1, 2003; 69(2): 179 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Baggish and D. R. Hill Antiparasitic Agent Atovaquone Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1163 - 1173. [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Atovaquone + proguanil for malaria prophylaxis DTB, October 1, 2001; 39(10): 73 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Korsinczky, N. Chen, B. Kotecka, A. Saul, K. Rieckmann, and Q. Cheng Mutations in Plasmodium falciparum Cytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2100 - 2108. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
